logo-loader
viewBiotec Pharmacon

Biotec Pharmacon strengthening market presence for its flagship Woulgan product

Christian Jorgensen, chief executive of Biotec Pharmacon (FRA:B4V),  talks Proactive London's Andrew Scott through the firm's two technology platforms - one of them's a unique enzymes platform where they sell to diagnostics and gene therapy companies.

The second platform is focused on BetaGlucens which develops and manufactures immune modulating compounds for the human health sectors. The technology's currently being used in a wound care product called Woulgan.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Group Eleven Resources finds a new investor in mining giant...

Group Eleven Resources (CVE: ZNG) CEO Bart Jaworski joined Steve Darling from Proactive Vancouver on Skype to discuss the news Glencore (LON: GLEN) has entered a shareholder agreement on Group Eleven’s Zinc Exploration in Ireland. Jaworski telling Proactive how the deal works and what it...

7 hours, 44 minutes ago

2 min read